Member Info for Flippineck

With the increasing successes of the trial I don’t think we’ll have any difficulty recruiting.

We are on track as previously stated in RNS earlier this year - 18th July.

I had some mining shares where the company had its assets in Sweden, it was a British based company, listed on AIM but it was also traded on a Swedish exchange. It made no difference to my holding but simply facilitated Swedish investors ability to trade on their exchange. Share rises over there tended to be mirrored by similar movements there.

However I am not an expert either. My view is it broadened the ease of trading, where you may have a significant investor base elsewhere.

Things have never looked better. New key personnel, Christina is a breath of fresh air, confidence oozing out of the last presentation and Premier league members on the SOB. More news very soon.

On the other hand there is a short open, new posters/traders are popping up with negative views and we have an analyst with either a lack of knowledge or an ulterior motive.

So who do you listen to - the professionals or the unknown traders and individuals on a bulletin board?

So treatment by AVA6000 results in “ extension of the plasma half-life by 40%”.

I seem to remember a certain poster obsessingly posting his concerns re problems with half-life!!

In the presentation Francis,VP Chemistry said

“ with dox the payload is cleared quite slowly. There is no need to keep it there longer for AVA6000”

In other words both seem similar in that respect.

Well certainly MotormouthRob is a busy boy. Starting at 4.58am today he has managed 41 posts on 11 different shares. I can’t help feeling he may be a trader with an agenda! Oh to be an expert on so many shares - the guy’s a genius.

CC is clearly a great motivator and team builder.

She knows how to lead - clear goals and how to get there, everybody recognised for the part they have to play. She is a real breath of fresh air.

Ice

You are correct. I emailed them a couple of months back, querying their shorting of AVCT and their ethics. I did get a reply very quickly

“GSA Capital is a quantitative, systematic trading firm. At any one time we have huge numbers of positions across asset classes and global liquid markets.As a quantitative firm our positions are determined by algorithms and not through fundamentals”.

In other words they are saying “ nothing to do with us, it’s the machines”!

Only - not once!

We know therapeutics is the “favourite son” and rightly so. However we have seen quite a bit in the news lately about the progress and benefits of early diagnosis.

Whilst I was surprised by the diagnostics acquisitions, it does seem they are well run businesses, pretty active in terms of communicating what they do and I wouldn’t be at all surprised to hear they are now profitable. Maybe the second son will turn out well also.

The company said many moons ago “ we know what we’ve got” and once they know the exact state of play at the moment. I think CC is a smart cookie and probably much more street wise than Al.

The share price seems to have a bit of a spring in its step at the moment and I really feel we may be turning a corner here.

GLA

I believe chemotherapy will be around for a long time, especially if side effects can be minimised or even eliminated. It is a long established treatment and change takes time.

New treatments will obviously come along but Health Authorities have stretched budgets. They need to opt for what is the best and most cost effective treatment for the majority of patients. Cancer is such a widespread disease. Very expensive new treatments, no matter how effective, could not realistically be given to the masses in my view .

As we live longer than previous generations the strain on budgets becomes even greater. It is hard to imagine there will ever be enough funding in the NHS (for example) to treat all the things that can be treated for all of the people. On a daily basis clinicians are faced with difficult choices.

Agree totally notrex. There are rumours he’s been demoted and is in line for Corporal punishment.

Very pleased we are working with SOFIE as I believe we have been in discussions with them for some time.

It is apparent that cancers come in very many shapes and forms and the ability to improve targeting in order to have the best possible treatment for each particular patient is to be applauded.

One size fits all is therefore not the way to go and Avacta (and others) realise that and are working towards more tailor made treatments. Sounds good to me.

The truth- not sure we can comment on FDA timelines, something we have no control over. Could it not be seen as somewhat arrogant and possibly counter productive?

Another one just turned up. Talk about buses!

Busy boy Bellamy.

21 posts so far today - all negative.

Posting pie chart looks like a dart board.

Says it all really.

Ben, those you talk of have very short term horizons. This isn’t a sprint but we may well have a sprint finish!

Deutsche Bank has a troubled recent history with regulators and prosecutors. Various sanctions have been imposed on the bank and it has paid big fines re money laundering issues and allegations of enabling tax violations, price fixing and foreign bribery. All according to Google.

I don’t think their advice can be regarded as sound. Best ignored.

Yep, Thorn has zero credibility. His posts can be safely ignored.

He should read up more and post less.

From memory PL I think he wasn’t too bad on adding up - it was the subtracting thingimmy that got him stumped.